Vitiligo Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech

The Key Vitiligo Companies in the market include - Incyte, Abbvie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others.

The Vitiligo market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vitiligo pipeline products will significantly revolutionize the Vitiligo market dynamics.

DelveInsight's "Vitiligo Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Vitiligo market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Vitiligo market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vitiligo Market Forecast [https://www.delveinsight.com/sample-request/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Vitiligo Market Report:

*
The Vitiligo market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2025, STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology firm focused on developing, commercializing, and marketing innovative dermatologic treatment products, announced the findings of a newly published study in Japan. The study further confirms the technological benefits of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology compared to other UVB light sources, which are less precise and lack the repetition rate and fluence capabilities of Excimer Light for treating conditions such as Vitiligo, Psoriasis, Alopecia Areata, and Atopic Dermatitis.

*
In February 2025, Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company specializing in host-directed therapies for immuno-inflammatory diseases, today announced its financial results for the quarter ending December 31, 2024, along with a business update. During this period, the company made progress with its lead asset, EB06, an anti-CXCL10 monoclonal antibody candidate aimed at providing effective and lasting treatment for vitiligo.

*
In January 2025, VYNE Therapeutics, a US-based pharmaceutical company, completed patient enrollment in its randomized Phase IIb clinical trial evaluating VYN201 gel (repibresib) for the treatment of non-segmental vitiligo. This double-blind, vehicle-controlled study is examining the safety, pharmacokinetics, and effectiveness of a once-daily application of the gel across three dosage groups-1%, 2%, and 3%-in comparison to a vehicle.

*
In May 2024, Edesa Biotech, Inc. (NASDAQ: EDSA) is preparing to launch a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo in patients. Vitiligo is a condition where certain areas of the skin lose color, and non-segmental vitiligo is marked by patches on both sides of the body. This condition occurs when pigment-producing cells (melanocytes) either die or stop producing melanin, often due to autoimmune diseases, genetics, or a triggering event such as stress, sunburn, or skin trauma.

*
The findings indicate that in 2023, the United States made up approximately 60% of the total diagnosed prevalent cases of vitiligo in the 7MM.

*
In the EU4 and the UK, Germany had the highest share of vitiligo patients, followed by the UK, while Spain had the lowest patient share.

*
According to estimates, there were 493,000 treated cases of vitiligo in the 7MM in 2023.

*
According to DelveInsight's estimates, the 12-month prevalence of vitiligo in the 7MM was evaluated at 8.2 million in 2023, with anticipated growth over the study period (2020-2034).

*
Among those diagnosed, the majority of cases in the 7MM are attributed to non-segmental vitiligo. While the diagnosis rate for vitiligo ranges from 40% to 60% across these regions, the treatment rate is approximately 10%.

*
Key Vitiligo Companies: Incyte, Abbvie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others

*
Key Vitiligo Therapies: OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others

Vitiligo Overview

Vitiligo is a skin condition characterized by the loss of pigment-producing cells called melanocytes, which results in white patches or depigmentation on the skin. These patches can appear anywhere on the body and vary in size and shape. Vitiligo can affect people of any age, gender, or ethnic group, but it is more noticeable in individuals with darker skin tones.

Get a Free sample for the Vitiligo Market Report:

https://www.delveinsight.com/report-store/vitiligo-market [https://www.delveinsight.com/report-store/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Vitiligo Market

The dynamics of the Vitiligo market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2020-2034.

Vitiligo Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Vitiligo Epidemiology Segmentation:

The Vitiligo market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Vitiligo

*
Prevalent Cases of Vitiligo by severity

*
Gender-specific Prevalence of Vitiligo

*
Diagnosed Cases of Episodic and Chronic Vitiligo

Download the report to understand which factors are driving Vitiligo epidemiology trends @ Vitiligo Epidemiological Insights [https://www.delveinsight.com/sample-request/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Vitiligo Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vitiligo market or expected to get launched during the study period. The analysis covers Vitiligo market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vitiligo Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Vitiligo Therapies and Key Companies

*
OPZELURA (ruxolitinib cream): Incyte

*
RINVOQ (upadacitinib): Abbvie

*
Ritlecitinib: Pfizer

*
Afamelanotide: Clinuvel, Inc.

*
Phimelanotide - Clinuvel Pharmaceuticals

*
BNZ-1: Bioniz Therapeutics

*
TAGX-0003: TAGCyx Biotechnologies

*
TT-01: Temprian Therapeutics

*
ATI-1777: Aclaris Therapeutics

*
AC-1101: TWi Biotechnology

*
Cerdulatinib: Dermavant Sciences

*
AMG 714: Amgen

*
Ritlecitinib: Pfizer

*
Ruxolitinib: Incyte Corporation

To know more about Vitiligo treatment, visit @ Vitiligo Medications [https://www.delveinsight.com/sample-request/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Vitiligo Market Drivers

*
Increasing awareness

*
Demand of novel therapies

*
Large patient pool and better healthcare infrastructure

Vitiligo Market Barriers

*
Patient compliance

*
Chronic nature of disease and long term therapy

*
Lack of adequate financial assistance & stringent regulatory procedure

Scope of the Vitiligo Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Vitiligo Companies: Incyte, Abbvie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others

*
Key Vitiligo Therapies: OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others

*
Vitiligo Therapeutic Assessment: Vitiligo current marketed and Vitiligo emerging therapies

*
Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Vitiligo Unmet Needs, KOL's views, Analyst's views, Vitiligo Market Access and Reimbursement

Discover more about therapies set to grab major Vitiligo market share @ Vitiligo Treatment Landscape [https://www.delveinsight.com/sample-request/vitiligo-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Vitiligo Market Report Introduction

2. Executive Summary for Vitiligo

3. SWOT analysis of Vitiligo

4. Vitiligo Patient Share (%) Overview at a Glance

5. Vitiligo Market Overview at a Glance

6. Vitiligo Disease Background and Overview

7. Vitiligo Epidemiology and Patient Population

8. Country-Specific Patient Population of Vitiligo

9. Vitiligo Current Treatment and Medical Practices

10. Vitiligo Unmet Needs

11. Vitiligo Emerging Therapies

12. Vitiligo Market Outlook

13. Country-Wise Vitiligo Market Analysis (2020-2034)

14. Vitiligo Market Access and Reimbursement of Therapies

15. Vitiligo Market Drivers

16. Vitiligo Market Barriers

17. Vitiligo Appendix

18. Vitiligo Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vitiligo-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-pfizer-clinuvel-inc-clinuvel-pharmaceuticals-bioniz-therapeutics-tagcyx-biotech]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.